472 related articles for article (PubMed ID: 17884023)
21. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
22. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult.
Tripanichkul W; Sripanichkulchai K; Duce JA; Finkelstein DI
Brain Res; 2007 Aug; 1164():24-31. PubMed ID: 17640623
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
24. NF-kappaB mediates MPP+-induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1.
Yang HJ; Wang L; Xia YY; Chang PN; Feng ZW
Neurochem Int; 2010 Jan; 56(1):128-34. PubMed ID: 19778565
[TBL] [Abstract][Full Text] [Related]
25. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
Kubo K; Inada T; Shingu K
Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
[TBL] [Abstract][Full Text] [Related]
26. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
27. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
[TBL] [Abstract][Full Text] [Related]
29. Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
Guo L; Li Y; Li W; Qiu J; Du J; Wang L; Zhang T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1221-1231. PubMed ID: 36054693
[TBL] [Abstract][Full Text] [Related]
30. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Nishi K
Brain Res; 1997 Oct; 771(1):133-41. PubMed ID: 9383016
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Ghosh A; Roy A; Matras J; Brahmachari S; Gendelman HE; Pahan K
J Neurosci; 2009 Oct; 29(43):13543-56. PubMed ID: 19864567
[TBL] [Abstract][Full Text] [Related]
33. JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease.
Huang Q; Du X; He X; Yu Q; Hu K; Breitwieser W; Shen Q; Ma S; Li M
Exp Neurol; 2016 Mar; 277():296-304. PubMed ID: 26515688
[TBL] [Abstract][Full Text] [Related]
34. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
Ito T; Suzuki K; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
[TBL] [Abstract][Full Text] [Related]
35. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
37. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
38. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
Kim JI; Yang EJ; Lee MS; Kim YS; Huh Y; Cho IH; Kang S; Koh HK
Int J Neurosci; 2011 Apr; 121(4):209-17. PubMed ID: 21265705
[TBL] [Abstract][Full Text] [Related]
39. Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease.
Goldberg NR; Haack AK; Meshul CK
Neuroscience; 2011 Jan; 172():443-52. PubMed ID: 20933577
[TBL] [Abstract][Full Text] [Related]
40. Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia.
Smeyne M; Goloubeva O; Smeyne RJ
Glia; 2001 Apr; 34(2):73-80. PubMed ID: 11307156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
